Enhanced Immunosuppressive Properties of Human Mesenchymal Stem Cells Primed by Interferon-γ

EBioMedicine

Volumn 28, Issue , 2018, Pages 261-273

  Kim, Dae Seong ^a,b   Jang, In Keun ^c   Lee, Myoung Woo ^a,b   Ko, Young Jong ^a   Lee, Doo Hoon ^c   Lee, Ji Won ^a   Sung, Ki Woong ^a   Koo, Hong Hoe ^a,b,d   Yoo, Keon Hee ^a,b,d  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Biomedical Research Institute   (South Korea)

^d Sungkyunkwan University   (South Korea)

Author keywords

Cell therapy; Graft versus host disease; Indoleamine 2,3 dioxygenase; Interferon ; Mesenchymal stem cell

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; STAT1 PROTEIN; JANUS KINASE; PHYTOHEMAGGLUTININ; TOLL LIKE RECEPTOR 3;

ADIPOSE TISSUE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; GRAFT VERSUS HOST REACTION; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL STEM CELL; MICROARRAY ANALYSIS; MOUSE; NOD SCID MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; SURVIVAL RATE; T LYMPHOCYTE; WHARTON JELLY; ANIMAL; BIOLOGICAL MODEL; CELL SEPARATION; COCULTURE; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION PROFILING; HUMAN; MESENCHYMAL STROMA CELL; METABOLISM; MONONUCLEAR CELL; NONOBESE DIABETIC MOUSE; SCID MOUSE;

ANIMALS; CELL SEPARATION; COCULTURE TECHNIQUES; DOWN-REGULATION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOSUPPRESSION; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; JANUS KINASES; LEUKOCYTES, MONONUCLEAR; MESENCHYMAL STROMAL CELLS; MICE, INBRED NOD; MICE, SCID; MODELS, BIOLOGICAL; PHYTOHEMAGGLUTININS; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TOLL-LIKE RECEPTOR 3;

EID: 85040649839     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2018.01.002     Document Type: Article

References (51)

1. Ankrum, J.A., Ong, J.F., Karp, J.M., Mesenchymal stem cells: immune evasive, not immune privileged. Nat. Biotechnol. 32 (2014), 252–260.
2. Asavaroengchai, W., Wang, H., Wang, S., Wang, L., Bronson, R., Sykes, M., Yang, Y.G., An essential role for IFN-gamma in regulation of alloreactive CD8 T cells following allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 13 (2007), 46–55.
3. Augello, A., Tasso, R., Negrini, S.M., Amateis, A., Indiveri, F., Cancedda, R., Pennesi, G., Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur. J. Immunol. 35 (2005), 1482–1490.
4. Baksh, D., Song, L., Tuan, R.S., Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. J. Cell. Mol. Med. 8 (2004), 301–316.
5. Barry, F.P., Murphy, J.M., Mesenchymal stem cells: clinical applications and biological characterization. Int. J. Biochem. Cell Biol. 36 (2004), 568–584.
6. Bucher, C.M., Passweg, J.R., Towards rational graft-versus-host disease prophylaxis. Haematologica 97 (2012), 1779–1780.
7. Bürgler, D., Medinger, M., Passweg, J., Fischmann, A., Bucher, C., Intra-arterial catheter guided steroid administration for the treatment of steroid-refractory intestinal GvHD. Leuk. Res. 38 (2014), 184–187.
8. Caplan, A.I., Mesenchymal stem cells. J. Orthop. Res. 9 (1991), 641–650.
9. Chan, J.L., Tang, K.C., Patel, A.P., Bonilla, L.M., Pierobon, N., Ponzio, N.M., Rameshwar, P., Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood 107 (2006), 4817–4824.
10. Chen, X., Armstrong, M.A., Li, G., Mesenchymal stem cells in immunoregulation. Immunol. Cell Biol. 84 (2006), 413–421.
11. Dazzi, F., Krampera, M., Mesenchymal stem cells and autoimmune diseases. Best Pract. Res. Clin. Haematol. 24 (2011), 49–57.
12. English, K., French, A., Wood, K.J., Mesenchymal stromal cells: facilitators of successful transplantation?. Cell Stem Cell 7 (2010), 431–442.
13. Fallarino, F., Grohmann, U., Using an ancient tool for igniting and propagating immune tolerance: IDO as an inducer and amplifier of regulatory T cell functions. Curr. Med. Chem. 18 (2011), 2215–2221.
14. Koç O.N., Gerson, S.L., Cooper, B.W., Dyhouse, S.M., Haynesworth, S.E., Caplan, A.I., Lazarus, H.M., Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J. Clin. Oncol. 18 (2000), 307–316.
15. Krampera, M., Mesenchymal stromal cells: more than inhibitory cells. Leukemia 25 (2011), 565–566.
16. Le Blanc, K., Tammik, C., Rosendahl, K., Zetterberg, E., Ringdén, O., HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp. Hematol. 31 (2003), 890–896.
17. Lee, M.W., Choi, J., Yang, M.S., Moon, Y.J., Park, J.S., Kim, H.C., Kim, Y.J., Mesenchymal stem cells from cryopreserved human umbilical cord blood. Biochem. Biophys. Res. Commun. 320 (2004), 273–278.
18. Medinger, M., Tichelli, A., Bucher, C., Halter, J., Dirnhofer, S., Rovo, A., Passweg, J., Tzankov, A., GVHD after allogeneic haematopoietic SCT for AML: angiogenesis, vascular endothelial growth factor and VEGF receptor expression in the BM. Bone Marrow Transplant. 48 (2013), 715–721.
19. Meirelles, Lda S., Fontes, A.M., Covas, D.T., Caplan, A.I., Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 20 (2009), 419–427.
20. Meisel, R., Zibert, A., Laryea, M., Göbel, U., Däubener, W., Dilloo, D., Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103 (2004), 4619–4621.
21. Mitchell, K.E., Weiss, M.L., Mitchell, B.M., Martin, P., Davis, D., Morales, L., Helwig, B., Beerenstrauch, M., Abou-Easa, K., Hildreth, T., Troyer, D., Medicetty, S., Matrix cells from Wharton's jelly form neurons and glia. Stem Cells 21 (2003), 50–60.
22. Müller, M., Carter, S., Hofer, M.J., Campbell, I.L., The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity - a tale of conflict and conundrum. Neuropathol. Appl. Neurobiol. 36 (2010), 368–387.
23. Munn, D.H., Sharma, M.D., Mellor, A.L., Ligation of B7-1/B7-2 by human CD4 + T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol. 172 (2004), 4100–4110.
24. Nauta, A.J., Fibbe, W.E., Immunomodulatory properties of mesenchymal stromal cells. Blood 110 (2007), 3499–3506.
25. Opitz, C.A., Litzenburger, U.M., Lutz, C., Lanz, T.V., Tritschler, I., Köppel, A., Tolosa, E., Hoberg, M., Anderl, J., Aicher, W.K., Weller, M., Wick, W., Platten, M., Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 27 (2009), 909–919.
26. Phinney, D.G., Biochemical heterogeneity of mesenchymal stem cell populations: clues to their therapeutic efficacy. Cell Cycle 6 (2007), 2884–2889.
27. Phinney, D.G., Functional heterogeneity of mesenchymal stem cells: implications for cell therapy. J. Cell. Biochem. 113 (2012), 2806–2812.
28. Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Douglas, R., Mosca, J.D., Moorman, M.A., Simonetti, D.W., Craig, S., Marshak, D.R., Multilineage potential of adult human mesenchymal stem cells. Science 284 (1999), 143–147.
29. Polchert, D., Sobinsky, J., Douglas, G., Kidd, M., Moadsiri, A., Reina, E., Genrich, K., Mehrotra, S., Setty, S., Smith, B., Bartholomew, A., IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur. J. Immunol. 38 (2008), 1745–1755.
30. Prockop, D.J., Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276 (1997), 71–74.
31. Qian, L., Wu, Z., Shen, J., Advances in the treatment of acute graft-versus-host disease. J. Cell. Mol. Med. 17 (2013), 966–975.
32. Ren, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A.I., Zhao, R.C., Shi, Y., Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2 (2008), 141–150.
33. Reyes, M., Lund, T., Lenvik, T., Aguiar, D., Koodie, L., Verfaillie, C.M., Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 98 (2001), 2615–2625.
34. Ringdén, O., Remberger, M., Svahn, B.M., Barkholt, L., Mattsson, J., Aschan, J., Le Blanc, K., Gustafsson, B., Hassan, Z., Omazic, B., Svenberg, P., Solders, G., von Döbeln, U., Winiarski, J., Ljungman, P., Malm, G., Allogeneic hematopoietic stem cell transplantation for inherited disorders: experience in a single center. Transplantation 81 (2006), 718–725.
35. Ringdén, O., Uzunel, M., Rasmusson, I., Remberger, M., Sundberg, B., Lönnies, H., Marschall, H.U., Dlugosz, A., Szakos, A., Hassan, Z., Omazic, B., Aschan, J., Barkholt, L., Le Blanc, K., Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81 (2006), 1390–1397.
36. Ruutu, T., van Biezen, A., Hertenstein, B., Henseler, A., Garderet, L., Passweg, J., Mohty, M., Sureda, A., Niederwieser, D., Gratwohl, A., de Witte, T., Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 47 (2012), 1459–1464.
37. Ryan, J.M., Barry, F., Murphy, J.M., Mahon, B.P., Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin. Exp. Immunol. 149 (2007), 353–363.
38. Sato, K., Ozaki, K., Oh, I., Meguro, A., Hatanaka, K., Nagai, T., Muroi, K., Ozawa, K., Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 109 (2007), 228–234.
39. Sekiya, I., Larson, B.L., Smith, J.R., Pochampally, R., Cui, J.G., Prockop, D.J., Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells 20 (2002), 530–541.
40. Soleymaninejadian, E., Pramanik, K., Samadian, E., Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am. J. Reprod. Immunol. 67 (2012), 1–8.
41. Sotiropoulou, P.A., Perez, S.A., Salagianni, M., Baxevanis, C.N., Papamichail, M., Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells 24 (2006), 462–471.
42. Spaggiari, G.M., Capobianco, A., Abdelrazik, H., Becchetti, F., Mingari, M.C., Moretta, L., Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111 (2008), 1327–1333.
43. Stec, M., Baran, J., Baj-Krzyworzeka, M., Weglarczyk, K., Gozdzik, J., Siedlar, M., Zembala, M., Chemokine receptors and chemokine production by CD34 + stem cell-derived monocytes in response to cancer cells. Anticancer Res. 32 (2012), 4749–4753.
44. Tan, P.H., Bharath, A.K., Manipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases. Expert Opin. Ther. Targets 13 (2009), 987–1012.
45. Vogel, W., Grünebach, F., Messam, C.A., Kanz, L., Brugger, W., Bühring, H.J., Heterogeneity among human bone marrow-derived mesenchymal stem cells and neural progenitor cells. Haematologica 88 (2003), 126–133.
46. Wang, H., Asavaroengchai, W., Yeap, B.Y., Wang, M.G., Wang, S., Sykes, M., Yang, Y.G., Paradoxical effects of IFN-gamma in graft-versus-host disease reflect promotion of lymphohematopoietic graft-versus-host reactions and inhibition of epithelial tissue injury. Blood 113 (2009), 3612–3619.
47. Wang, Y., Chen, X., Cao, W., Shi, Y., Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat. Immunol. 15 (2014), 1009–1016.
48. Waterman, R.S., Tomchuck, S.L., Henkle, S.L., Betancourt, A.M., A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS One, 5, 2010, e10088.
49. Waterman, R.S., Henkle, S.L., Betancourt, A.M., Mesenchymal stem cell 1 (MSC1)-based therapy attenuates tumor growth whereas MSC2-treatment promotes tumor growth and metastasis. PLoS One, 7, 2012, e45590.
50. Yamamoto, M., Ota, A., Hori, T., Imai, S., Sohma, H., Suzuki, N., Hatakeyama, N., Inazawa, N., Ito, Y.M., Kimura, H., Tsutsumi, H., Kokai, Y., Early expression of plasma CCL8 closely correlates with survival rate of acute graft-vs-host disease in mice. Exp. Hematol. 39 (2011), 1101–1112.
51. Zuk, P.A., Zhu, M., Mizuno, H., Huang, J., Futrell, J.W., Katz, A.J., Benhaim, P., Lorenz, H.P., Hedrick, M.H., Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 7 (2001), 211–228.